Study Evaluates Safety, Tolerability of Drug for Acute Decompensated Heart Failure

 

July 1, 2009

July 1, 2009 – Cardioxyl Pharmaceuticals Inc. announced today the initiation of a phase I/IIa dose-escalation study of lead drug candidate, CXL-1020, for the treatment of acute decompensated heart failure (ADHF).

The study has already begun enrollment, and researchers dosed the first patient in June 2009. The study will evaluate the safety and tolerability of CXL-1020 and its specific effects on noninvasive hemodynamic parameters in patients with chronic stable heart failure. It will also evaluate the pharmacokinetics of CXL-1020.

The company hopes the drug will provide a safe and effective therapy to enhance both diastolic and systolic function while concomitantly reducing vascular resistance. CXL-1020 is a novel, first-in-class, small molecule nitroxyl (HNO) donor therapeutic drug candidate.

“In preclinical trials, CXL-1020 has exhibited a very attractive suite of physiologic effects in canine models of heart failure,” said Wilson S. Colucci, M.D., Boston University Medical Center Cardiovascular Center and Steering Committee chair. “We look forward to evaluating the safety and tolerability, as well as the hemodynamic effects of CXL-1020 in this dose-escalation study.”

For more information: www.cardioxyl.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.